The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions | Zendy

Baptist Gallwitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions

Author(s) -

Baptist Gallwitz

Publication year - 2006

Publication title -

the review of diabetic studies

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.701

H-Index - 41

eISSN - 1614-0575

pISSN - 1613-6071

DOI - 10.1900/rds.2006.3.208

Subject(s) - rosiglitazone , type 2 diabetes , incretin , thiazolidinedione , insulin resistance , medicine , beta cell , beta (programming language) , diabetes mellitus , function (biology) , pharmacology , bioinformatics , endocrinology , islet , biology , computer science , microbiology and biotechnology , programming language

This article gives an overview of two recent trials investigating rosiglitazone, a thiazolidinedione, in its potential to prevent type 2 diabetes (T2D) and in its effectiveness in monotherapy. Thiazolidinediones are among the most important developments of recent years for combating T2D and therefore worth to revisit. The possible influence of thiazolidines in improving beta-cell function is discussed as well as the potential effects on insulin resistance and obesity. Novel, incretin-based therapies (GLP-1 analogues and DPP-4 inhibitors) and their effects on beta-cell function and beta-cell mass are also summarized and critically evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research